Nurix reported results for the quarter ended May 31, 2026, with total revenue of $9.0 million and a net loss of $89.5 million, or $(0.81) per share. The company had $443.5 million in cash, cash equivalents and marketable securities as of May 31, 2026, and expects a $700 million upfront payment from Roche upon closing of a global collaboration. Nurix highlighted progress across its bexobrutideg clinical program, expansion into immunology and neurology, and ongoing advancement of multiple preclinical and partnered programs.

Financial Highlights

  • Total revenue: $9.0 million for the three months ended May 31, 2026 (compare: $44.1 million for the three months ended May 31, 2025).
  • Collaboration revenue: $9.043 million for the three months ended May 31, 2026; license revenue was $— in the quarter (prior period included $30.0 million license revenue).
  • Research and development expense: $87.7 million for the three months ended May 31, 2026 (compare: $78.1 million).
  • General and administrative expense: $15.6 million for the three months ended May 31, 2026 (compare: $14.3 million).
  • Net loss: $(89.5) million, or $(0.81) per share, for the three months ended May 31, 2026 (compare: $(43.5) million, or $(0.52) per share).
  • Cash, cash equivalents and marketable securities: $443.5 million as of May 31, 2026 (November 30, 2025: $592.9 million); company expects a $700 million upfront payment from Roche in Q3 2026.

Business Highlights

  • Entered a global co-development and co-commercialization collaboration with Roche for bexobrutideg (NX-5948) across malignant hematology, immunology and neurology; potential total payments up to $2.3 billion, including a $700 million upfront payment expected within 30 days of effectiveness.
  • Collaboration includes shared development costs (Nurix 40%, Roche 60%), U.S. profit/loss sharing (50/50) and tiered ex-U.S. royalties; agreement subject to customary closing conditions and antitrust clearances.
  • Presented updated clinical data for bexobrutideg at EHA 2026 showing promising activity in CLL/SLL: Phase 1a median progression-free survival 22.1 months and ORR 83%; Phase 1b cohort ORRs of 92.9% and 84.2% in distinct patient cohorts with many patients remaining on treatment at cutoff.
  • Advancing registrational and confirmatory trials: enrollment ongoing in DAYBreak CLL-201 (pivotal Phase 2); preparations underway for DAYBreak CLL-306 (global Phase 3 vs. pirtobrutinib) with first-patient dosing anticipated mid-2026; planning combination studies and additional NX-5948-301 cohorts.
  • Expansion into immunology and neurology: preclinical and Phase 1 translational data support potential in chronic spontaneous urticaria and plans for Phase 2 studies in CSU and multiple sclerosis; evaluating new oral tablet formulation in SAD/MAD healthy volunteer study.
  • Broader pipeline progress and partnerships: completed enrollment in current dose-escalation cohorts for NX-1607 (CBL-B) and zelebrudomide; continued collaborations with Sanofi (STAT6 degrader) and Gilead (IRAK-4 degrader) with opt-in/co-development rights and recent $2 million milestone from Sanofi.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.